SELECT-NEXT studies patients on stable dosing but with inaquate response to conventional synthetic disease modifying anti-rheumatic drugs (csDMARDs), SELECT-BEYOND studies patients on csDMARDs and with inadequate response to biologic DMARDs, and SELECT MONOTHERAPY is specific to patients with inadequate response to stable dosing of methotrexate.